NEW YORK – After raising $103 million in a Series C funding round earlier this month, cancer sequencing firm Personal Genome Diagnostics now aims to invest in its commercial infrastructure and strike more agreements with diagnostic and pharmaceutical firms.
Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.